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ABSTRACT: Background: Before the occurrence
of motor symptoms permits the clinical diagnosis of
Parkinson’s disease (PD), about or even more than 50%
of the dopaminergic neurons of the substantia nigra
have degenerated. This time be called the prodromal
phase of PD.
Objective: To evaluate the time span from onset of ﬁrst
prodromal symptoms to the initial diagnosis of PD as
well as the order of symptom occurrence.
Methods: Retrospective study of 93 consecutively
interviewed PD patients without dementia and 93 sex
and age matched controls free of neurodegenerative
disorders. A standardized in-house telephone work-
sheet assessing 19 nonmotor and six early motor signs
was used.
Results: A total of 98.8% of all patients interviewed
reported to have experienced prodromal symptoms
prior to receiving the initial diagnosis of PD. Patients
noticed an average of 7.6 different symptoms during
this time interval. The mean time span between the
recalled onset of any one symptom and PD diagnosis
was 10.2 years. In both groups, the course of prodro-
mal sign onset was associated with early neuropatho-
logical disease stages proposed by Braak.
Outlook: These retrospectively gathered data conﬁrm
the existence of a long prodromal phase for PD that is
consistent with neuropathological staging. A standar-
dized questionnaire assessing such early symptoms
may be helpful in identifying subjects at high risk for PD
while they are still in the prodromal phase of the disor-
der. V C 2011 Movement Disorder Society
Key Words: Parkinson’s disease/parkinsonism; pro-
dromal phase; Braak staging
When Parkinson’s disease (PD) is noticed by patients
and diagnosed by clinicians, about or even more than
50% of the dopaminergic cells in the substantia nigra (SN)
are reported to have degenerated.
1 The time span between
the onset of neurodegeneration and manifestation of the
typical motor symptoms is referred to as premotor or pro-
dromal phase of PD.
2–4 The duration of this phase prior to
initial diagnosis of PD is still a matter of debate
5 and has
been estimated to last for years
6 or even decades.
4,7,8
This premotor phase, however, is not clinically
silent. Premotor symptoms are known to antecede the
typical clinical symptom constellation (akinesia plus
rigidity and/or tremor with difference in severity of
side affection) leading to the clinical diagnosis (UK
Brain Bank criteria).
9
Early symptoms are probably caused by affection of
lower brainstem and spinal cord areas as well as the olfac-
tory bulb. The appearance of these symptoms has been
suggested to be accompanied or caused by the presence
Lewy pathology at these sites before the SN is involved to
such a degree that motor signs permit the diagnosis of
PD.
10 A number of additional studies have provided evi-
dence that constipation
11 and other signs of autonomic
dysfunction,
2,12 hyposmia,
13 pain,
3 REM-sleep-behavior-
disorder (RBD)
14,15 neuropsychiatric complaints (anxiety,
depression), and minor cognitive deﬁcits
16–18 may also be
subsumed under this group. Mild motor signs, such as an
asymmetric arm swing, which cannot unambiguously be
classiﬁed as symptoms of PD, when occurring singularly,
may be attributable to the progressive cell loss of the SN
that is not severe enough to result in the classical clinical
presentation of PD.
9
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symptoms can precede PD diagnosis according to pub-
lished diagnostic criteria, we refer to this period in the
following as the prodromal phase.
Many PD patients seem to notice nonmotor and
early motor symptoms, as evidenced by the fact that
they go to see general practitioners with psychological
or painful musculoskeletal complaints more often than
controls, with an increasing rate of consultations 3–6
years prior to initial diagnosis.
19–22 Moreover, in a
prospective study, it could be shown that early unclear
motor signs, including stiffness, tremor of the extrem-
ities or head, slowed movements, feeling of lost bal-
ance and/or falls were reported by more than 70% of
those individuals in whom PD was diagnosed after a
mean follow-up of 5.8 years.
23
Because the chronology of such nonmotor and slight
motor symptoms is unknown, this retrospective study
aimed to characterize the prodromal period more clearly
by assessing patients’ perception of both these signs.
Methods
Patients and Recruitment
For this study, which was approved by the local ethical
committee, we questioned 93 consecutive patients with
idiopathic PD (according to UKBB clinical diagnostic cri-
teria
24), who were seen as outpatients by movement dis-
order specialists at the University of Tu ¨bingen,
Department of Neurodegeneration within a 12-months
period prior to the telephone interview. Under the same
conditions, 93 gender and age-matched control persons
free of neurodegenerative disorders were interviewed.
Inclusion criteria for PD patients were Hoehn & Yahr
stage 1–3 and ﬂuency in German language. Exclusion cri-
teria were signs of dementia according to the DSM-IV cri-
teria assessed by an experienced clinician and a score  
26 in the Mini-Mental-State-Examination,
25 evidence of
atypical Parkinsonian syndromes, severe head trauma or
other central neurological disorders. The control individ-
uals were recruited from a large sample of an epidemio-
logical population-based study of 812 persons (n ¼ 40)
26
and from a second, still unpublished cross-sectional study
of 555 persons (n ¼ 53). For both cross-sectional studies,
volunteers (>50 years of age) free of neurodegenerative
disorders were recruited with the help of advertisements
placed in local newspapers. All patients and controls
were invited by letter to participate in a telephone inter-
view of  45 min duration during which they would be
questioned about the occurrence of nonmotor and early
nonspeciﬁc motor symptoms.
Telephone Interview
The telephone interview was performed in a struc-
tured fashion using an in-house standardized work-
sheet. The interview consisted of 25 speciﬁc questions
designed to assess presence of 19 nonmotor and six
early motor symptoms in the patient history.
The following 19 nonmotor symptoms were subdi-
vided into six categories:
1. visual abnormalities: (1) disturbance of colour
vision;
2. sleep disturbances: signs of RBD, i.e., (2) crying
during sleep, (3) nightmares or (4) vivid dreams,
(5) limb movements during sleep or other sleep
disturbance e.g., (6) problems with staying asleep
or (7) falling asleep;
27
3. (8) anosmia or hyposmia;
4. autonomic dysfunction—(9) constipation, (10)
increased sweating, (11) seborrhoea and (12) or-
thostatic dizziness;
5. psychiatric complaints, including (13) anxiety, (14)
moodiness, (15) depression, or (16) lack of motiva-
tion in the performance of daily activities (apathy);
6. cognitive impairment or abnormalities, including
(17) problems to recall names and other essential
information, (18) forgetfulness and ﬁnding of
words or (19) slowed thinking (bradyphrenia).
The six additional questions for evaluating early
motor slowing (hereafter referred to as ‘‘early motor
signs’’) included: (20) hypophonia, (21) dysarthria, (22)
sialorrhoea as a result of reduced swallowing, (23) slow-
ing of ﬁne hand movements, (24) general slowing—bra-
dykinesia and (25) unilaterally reduced arm swing.
For each sign, participants were directed to respond
with ‘‘yes’’ or ‘‘no.’’ For afﬁrmative answers, partici-
pants were asked to report the time of the ﬁrst
perception in years before the diagnosis of PD was
made (patients) or the timespan in years (controls). For
PD patients, only the symptoms reported to
have started before the diagnosis of PD were counted.
The anticipated prodromal time span therefore was the
time of nonmotor or nonspeciﬁc symptom onset to ini-
tial diagnosis for the patients, for the controls it was the
time span of symptom onset to the interview.
Statistics
Statistical analyses were performed with SPSS 17.0 for
Windows SPSS (Chicago, IL, III). For the group compari-
son according to the occurrence of characteristics or cat-
egorical data Chi-square-test was applied (P < 0.05). For
variables with normal distribution (Kolmogoroff Smirn-
off Test P > 0.05) the Student’s t-test was applied, for all
other variables the Mann-Whitney U-Test was per-
formed. For analysis of the mean number of signs in dif-
ferent age ranges (Table 2), Bonferoni-correction for
multiple testing was applied (P ¼ 0.05/5 ¼ 0.01).
Demographical Data
Mean age of PD patients was 67.9 years 6 7.3 years,
mean age of controls was 67.7 6 7.2 years, (P ¼ 0.9).
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1.0). In the group of the PD patients 47.3% were H&Y
stage 1.0, 35.5%—2.0 and 17.2%—3.0. 25.8% patients
had a rigid-akinetic type of PD, in 28% a tremor-domi-
nant and in 46.2% a mixed form of PD was diagnosed.
The mean duration from diagnosis of PD to interview
was 5.9 6 5.7 years.
Results
Prodromal Symptoms in PD Patients
and Controls
98.9% of the PD patients and 97.4% of the controls
responded afﬁrmative to at least one question regard-
ing prodromal symptoms. 92.5% of the PD patients
and 90.3% of the controls reported one or more non-
motor sign(s), and 95.7% of the PD patients as
opposed to 37.6% of the controls experienced some
early nonspeciﬁc or slight motor symptoms (Table 1).
Six of 19 (31.6%) nonmotor and ﬁve of six (83.3%)
early motor symptoms were reported signiﬁcantly
more often by PD patients than by controls (Fig. 1).
The age of symptom onset did not signiﬁcantly dif-
fer for patients and controls with exception of three
symptoms (increased sweating, problems with falling
and with staying asleep, (Fig. 1). But taking all signs
together, there was a signiﬁcant group difference in
the age of onset of any ﬁrst sign, with earlier onset in
the group of PD patients at 51.2 (SD 11.6) years com-
pared with controls in whom the recalled age of ﬁrst
perception was 57.2 years (SD 10.3), P < 0.001.
In each age range starting from 41 years, PD
patients reported signiﬁcantly more prodromal signs
than controls (Table 2).
Time Course of Prodromal Symptoms in PD
The mean duration of the evaluated premotor and
early motor symptoms before the diagnosis of PD was
10.6 (SD 8.1) and 3.3 years (SD 2.7). The ﬁrst signs
noticed by the patients more than 10 years before di-
agnosis were disturbance of color vision, constipation,
anxiety, and symptoms of possible RBD, followed by
TABLE 1. Number of prodromal, nonmotor and early
motors signs in PD patients and controls
Number of signs out of 25 All prodromal Nonmotor Early motor
PD-patients,
n ¼ 93
Mean 7.6 4.8 2.8
SD 4 3.3 1.3
Range 0–16 0–13 0–6
Controls,
n ¼ 93
Mean 4 3.5 0.5
SD 2.8 2.4 0.8
Range 0–13 0–10 0–4
P-value (Mann-Whitney-test) <0.0001 0.017 <0.0001
FIG. 1. Illustration of hypothesis: Reported symptoms of PD patients and controls in the prodromal phase of PD with regard to mean age (years, y)
at onset (modified from
10 and
28). The schema of stages of PD and image of brain are used with friendly permission of Braak et al.
10 * P-value for
the test < 0.05. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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sense of smell and shortly before the diagnosis of the
PD-slight motor deﬁcits (Table 3, Fig. 1).
Time Course of Prodromal Symptoms
in Controls
All signs were listed in the order of their timely
occurrence (mean age at onset) from the earliest to the
latest (Fig. 1). Controls displayed a similar sequence
of symptom manifestation as PD patients but at
slightly higher ages, with signs related to RBD and
psychiatric complaints occurring earliest, followed by
constipation and hyposmia. Similarly, in controls the
age of onset for slight motor symptoms was higher
than for the PD group.
Discussion
Our aim was to identify the frequency and timely
occurrence of unspeciﬁc symptoms supposed to be
related to the prodromal phase of PD. In our study
population, the mean duration of this phase was 10.6
years. Based on previous neuroimaging and clinical
observations, a premotor phase with a probable dura-
tion of 10–13 years has been proposed.
8,19
The fact that the investigated prodromal symptoms
are more frequently reported in PD patients than in
controls underlines the existence of this phase preced-
ing the diagnosis of PD. In our cohort, PD patients
reported to have experienced an increasing number of
these symptoms with increasing age before the diagno-
sis of PD was made (Table 2).
The occurrence of these symptoms, which are other-
wise unspeciﬁc when evaluated singularly, appears to
correspond to the neuropathological staging of PD-
associated Lewy body (LB) pathology as proposed
by Braak et al.
10 and modiﬁed by Przuntek et al.
28
(Fig. 1).
According to the neuropathological staging of
ascending LB pathology, in Braak stage 1 neurodegen-
eration can be found in the olfactory bulb
29 and in
the lower brainstem comprising among others the dor-
sal motor nucleus of the vagal nerve and/or the inter-
mediate reticular zone
10,28 as well as in the
gastrointestinal tract.
30,31 The expected clinical presen-
tation for this stage would include reduced gastroin-
testinal motility, i.e., constipation and reduced
olfaction, which when regarded as prodromal PD
symptoms might occur up to 12 years before the diag-
nosis of PD. The patients in our cohort reported con-
stipation and hyposmia with a mean of 16.8 and 11.2
years prior to the diagnosis, respectively.
In Braak stage 2, LB pathology and neurodegenera-
tion have been reported to affect the brainstem includ-
ing noradrenergic and serotonergic nuclei, potentially
resulting in mood disorders such as anxiety (up to 20
years before PD diagnosis
17) or depression (approxi-
mately 10 years before motor manifestation
20) as well
as sleep disorders such as RBD, occurring at about
10–12.7 years before the diagnosis of PD in prospec-
tive studies.
14,32,33 Fitting well with this hypothesis,
patients of our cohort reported typical RBD symptoms
about 11–12.6 years before the diagnosis of PD as
well as symptoms of anxiety (13.7 years) and depres-
sion (10.2 years).
With progression to Braak stage 3, neurodegenera-
tion may affect the dopaminergic neurons in the SN,
resulting in the presentation of the ﬁrst, yet unspeciﬁc
motor symptoms which ﬁnally result in the typical
clinical presentation allowing PD diagnosis. According
to our data, these ﬁrst minimal motor signs such as
slight hypophonia or reduced arm swing may occur
about 4.7–2.2 years before the initial diagnosis can be
made.
Interestingly, the same chronology of prodromal
symptoms was also seen in the controls, however, in a
smaller number and at an older age. It may therefore
be hypothesized that the occurrence of prodromal symp-
toms reﬂects the tenuous border between the normal
process of aging and of a beginning neurodegeneration.
Recently published neuropathological data suggest that
TABLE 2. Mean number of signs for different age ranges (retrospectively gathered data)
< 40 years 41–50 years 51–60 years 61–70 years > 71 years
PD
n 9 3 8 25 51 3 1 3
Mean 0.72 1.9 3.6 5.3 5.9
SD 1.73 2.4 3 3.6 3.5
Range 0–10 0–9 0–14 0–10 2–14
Controls
n 9 3 9 27 83 4 3 4
Mean 0.26 0.3 1.2 2.3 2.8
SD 0.64 0.7 1.3 2 2
Range 0–3 0–3 0–6 0–6 0–6
P-value (Mann-Whitney-test) 0.175 <0.001 <0.001 0.01 <0.001
Bonferoni correction for multiple comparisons: signiﬁcance at P < 0.01.
GAENSLEN ET AL.
656 Movement Disorders, Vol. 26, No. 4, 2011the different stages of LB pathology are passed through
by all PD patients but that time of onset and the overall
duration of this process may vary by large.
34 Further-
more, LB pathology corresponding to Braak stages 1
a n d2h a sb e e nr e p o r t e di nu pt o2 3 . 7 %o fc l i n i c a l l y
healthy individuals,
35 interestingly similar to our clinical
ﬁndings also at older ages in relation to PD patients
with compatible LB pathology.
36 B a s e do nt h e s ed a t a ,i t
has been speculated that at least some of the clinically
healthy subjects with incidental LB might have been in
the prodromal phase of PD and could have developed
PD at higher age. This assumption can be supported by
the relationship of incidental LB disease with RBD,
37
hyposmia,
38 and presence of slight extrapyramidal
motor symptoms.
39
Taken together, these ﬁndings show that known pre-
motor symptoms occur in a high percentage of PD
patients and signiﬁcantly more frequent than in controls
up to 10 to 15 years before motor manifestation. More-
over, our ﬁndings suggest that a combination of these
symptoms, especially when they occur in a speciﬁc chro-
nology may help to identify persons at risk for PD.
As indicated above, some limitations of this study
need to be addressed. The main is the retrospective
design. For sure, it is difﬁcult for individuals to
remember whether they had some speciﬁc symptoms
and if so for how long they have realized them. There-
fore, data cannot be assumed to be entirely exact. Still,
the higher prevalence of symptoms prior to the diagno-
sis PD compared to matched controls is striking as is
the timely order of symptom manifestation and its anal-
ogy in both groups. However, not all symptoms are
perceived immediately at their ﬁrst occurrence, and
problems in assessment occur in both prospectively or
retrospectively designed studies. For example, reduced
olfaction may develop slowly, and may need a certain
amount of impairment before being realized by the
patient, whereas RBD could be noticed far earlier lead-
ing to a misinterpretation of timely succession, which
may also be reﬂected by our data. It is also important
to take into account, that the retrospective recall of the
time of onset of speciﬁc symptoms after many years
can only be an estimation. Therefore, some variation of
the time of onset derived from the retrospective recall,
and the actual occurrence of sings of neurodegeneration
must be considered.
In PD patients a time span of symptoms occurrence
to time of diagnosis was used, in controls a span of
occurrence to interview. This difference in calculation
endpoints needs to be accepted, as there is no time of
diagnosis in controls.
Another limitation is that the interview was per-
formed by telephone, without visual contact to the
interviewed persons. Hence, a lack of concentration
might not have been recognized by the investigator,
which may have lead to some bias to data acquisition.
On the other hand, all participants were invited
beforehand in written form therefore had enough time
to prepare for the interview situation in their familiar
surroundings. Moreover, the interview situation was
exactly the same for patients and controls—therefore,
possible shortcomings of the interview technique apply
to both groups investigated. However, the lack of vali-
dation of the questionnaire needs to be considered, as
this assessment tool had been designed for this study.
However, it was not meant to be a questionnaire,
therefore sensitivity and speciﬁcity for the included
questions has not been evaluated. The main purpose
of this worksheet was to establish comparable inter-
view situations for all participants for acquisition of
patients’ history information. To our knowledge, to
date, no validated questionnaire is available for assess-
ment of putative prodromal PD symptoms in patients
and controls. We hope, that the results of this study
may help in the deﬁnition of potentially valuable items
to be included in such a questionnaire.
Further bias to the data may arise from the selection
of interview questions, since for example not all
potential prodromal signs such as pain or erectile or
urinary dysfunction have been included.
Increasing effort is being put in neuroprotective
therapies. Therefore, additional diagnostic instruments
to facilitate a very early diagnosis of PD are of great
importance. A summary of the most probable risk fac-
tors reviewed in one questionnaire might be such a
tool, which could be easily applicable in patients at
TABLE 3. Mean duration of prodromal signs in PD
patients before the diagnosis of PD
PD-patients
Mean duration of symptoms before
the diagnosis of PD in years (SD)
Disturbance of color vision 22.3 (13.6)
Constipation 16.8 (5.7)
Anxiety 13.7 (7.5)
Nightmares 12.6 (7.5)
Involuntarily crying during sleep 12.5 (10)
Involuntarily limbs moving during sleep 11.9 (7.9)
Increased sweating 11.5 (9.6)
Hyposmia/anosmia 11.2 (11.1)
Vivid dreams 11 (6.2)
Moodiness 10.6 (7.7)
Problems with falling asleep 10.4 (8.6)
Depression 10.2 (9.7)
Problems with staying asleep 9.3 (6.6)
Apathy 8.8 (7.1)
Sialorrhoea 8.2 (6.4)
Orthostatic dizziness 8.1 (6.1)
Seborrhoea 5.9 (6.8)
Hypophonia 4.7 (5.2)
Forgetfulness 3.5 (2.9)
Slowing of ﬁne hand movements 3.2 (2.9)
Bradyphrenia 3.1 (2.5)
Problems to recall words 3.1 (2.4)
General bradykinesia 2.9 (1.9)
Dysarthria 2.4 (1.8)
Reduced arm swing 2.2 (2.1)
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spective investigations.
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